USPTO serial 87425888
SALUBRISBIO
Reviewed by CopyMark Law Group
Reg. 5748146Status 710
- Filing date
- Status date
- Registration date
- May 14, 2019
- Examiner
- KEELEY, ALISON REBECCA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SALUBRISBIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Futian Dist., Shenzhen, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Futian Dist., Shenzhen, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Futian Dist., Shenzhen, CN
Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy T. Wang
TIMOTHY T. WANG NI, WANG & MASSAND, PLLC8140 WALNUT HILL LANE,SUITE 500DALLAS, TX 75231UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Medicines for human purpose, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biological preparations for medical purposes, namely, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biochemical medicines, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Drugs for medical purposes in the nature of medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Injections, namely, vaccines and injectable medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of components of finished pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Dietetic substances adapted for medical use, namely, dietetic beverages and food for medical purposes, the foregoing dietetic food and beverages containing vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, restoratives, plant fibre, nutrition powder, nutrient capsule, nutrient tablets, and containing mineral food-supplements, the foregoing dietetic foods and beverages are used for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
- Other trademarks owned by SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.
- Other trademarks in Class 005
- Similar marks named SALUBRISBIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 28, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| May 14, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| May 14, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 26, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 26, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 6, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 25, 2019 | MREI | NOTICE OF REINSTATEMENT MAILED | — |
| Jan 23, 2019 | ADBS | 1(B) BASIS DELETED; NEW BASIS REQUESTED | — |
| Jan 22, 2019 | RGIA | REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED | — |
| Jan 22, 2019 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Dec 17, 2018 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Dec 17, 2018 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Nov 14, 2018 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Oct 9, 2018 | PCBG | PETITION TO DIRECTOR - CHANGE BASIS - GRANTED | — |
| Oct 5, 2018 | APET | ASSIGNED TO PETITION STAFF | — |
| Sep 24, 2018 | TPAD | TEAS PETITION TO AMEND BASIS RECEIVED | — |
| Sep 22, 2018 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 21, 2018 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Sep 6, 2018 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jul 18, 2018 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| Jul 17, 2018 | TPEX | SOU EXTENSION RECEIVED WITH TEAS PETITION | — |
| Jul 17, 2018 | PETG | PETITION TO REVIVE-GRANTED | — |
| Jul 17, 2018 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Jun 18, 2018 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 18, 2018 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| May 14, 2018 | EXT1 | SOU EXTENSION 1 FILED | — |
| Nov 14, 2017 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Sep 19, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 27, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 24, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 3, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 29, 2017 | NWAP | NEW APPLICATION ENTERED | — |